Estrella Immunopharma Treats First Patient With Two EB103 Doses in STARLIGHT-1 Expansion Phase
Bitget2026/10/15 22:45- Estrella Immunopharma reported encouraging initial tolerability in the first patient receiving two EB103 infusions in STARLIGHT-1’s dose-expansion phase for relapsed/refractory B-cell non-Hodgkin’s lymphoma.
- The patient received infusions three weeks apart, with no treatment-related serious adverse events reported during the first month.
- Previously reported dose-escalation results showed complete responses in all evaluable high-dose patients, with no treatment-related serious adverse events across nine treated patients.
- Expansion-cohort data will inform the pivotal trial strategy; additional safety and efficacy results are planned for future reporting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Avacta’s AVA6207 Overcomes Cancer Drug Resistance in Preclinical Studies
Preventing the Spread of AI Credit Risks! South Korean Financial Regulators Launch Inspections, Requiring Banks and Brokerages to Report AI-Related Exposures
As concerns rise over the risks of massive investments and debt financing in the artificial intelligence (AI) sector, South Korea's financial regulators have requested leading domestic financial institutions to disclose their risk exposure in the AI field.

Stonex sets initial price target for NXP at $340
Wells Fargo (WFC.US) doubles its IBIT holdings for clients as U.S. institutions significantly increase positions in Q3
According to the 13F report, Wells Fargo's client holdings of IBIT shares have doubled to nearly 50 million shares, equivalent to 30,553 BTC. Institutions such as Goldman Sachs and Bank of America have also significantly increased their holdings of spot bitcoin ETFs. Despite the current bitcoin price falling more than 20% from the quarter-end, institutional enthusiasm for allocation remains strong.
